# Laronde

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/laronde

- Industry: Biotechnology
- Headquarters: Cambridge, US
- Website: www.laronde.bio/
- Total disclosed funding: $471M
- Latest round: Series B (Aug 30, 2021)
- Investors on record: 7

## About

Based in Massachusetts, US, and founded in 2017 by founder and CEO Noubar Afeyan and Avak Kahvejian, the Laronde Inc. platform offers a way of modulating human biology. In August 2021, Laronde Inc. received USD 440 million in Series B funding from T. Rowe Price Associates, Inc., Invus, CPP Investments, Fidelity Management & Research Company, BlackRock, and Federated Hermes Kaufmann Funds.

Laronde Inc. offers eRNA-based non-immunogenic therapeutics supported by a digital and manufacturing infrastructure that can be programmed to express diverse proteins inside the body.

Laronde Inc. will use the funding to advance the development of its eRNA platform and a broad pipeline of programs across a number of therapeutic categories.

## Funding rounds

- Series B, Aug 30, 2021, $440M — Flagship Pioneering, T Rowe Price, CPP Investment Board, Invus [DUP], Fidelity Investments, BlackRock, Federated Hermes
- Series A, May 10, 2021, $31M — Flagship Pioneering

## Investors

- Flagship Pioneering (https://capitalatlas.ai/funds/flagship-pioneering) — Series A, Series B
- T Rowe Price (https://capitalatlas.ai/funds/t-rowe-price) — Series B
- CPP Investment Board — Series B
- Invus [DUP] — Series B
- Fidelity Investments (https://capitalatlas.ai/funds/fidelity-investments) — Series B
- BlackRock (https://capitalatlas.ai/funds/blackrock) — Series B
- Federated Hermes (https://capitalatlas.ai/funds/federated-hermes) — Series B